200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 941685-37-6
941685-37-6 | 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
CAS No: 941685-37-6 Catalog No: AG000BIK MDL No:MFCD13184797
Product Description
Catalog Number:
AG000BIK
Chemical Name:
1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
CAS Number:
941685-37-6
Molecular Formula:
C17H18N6
Molecular Weight:
306.3650
MDL Number:
MFCD13184797
IUPAC Name:
(3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
InChI:
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m0/s1
InChI Key:
HFNKQEVNSGCOJV-HNNXBMFYSA-N
SMILES:
N#CC[C@H](n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1
Properties
Complexity:
453
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
306.159g/mol
Formal Charge:
0
Heavy Atom Count:
23
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
306.373g/mol
Monoisotopic Mass:
306.159g/mol
Rotatable Bond Count:
4
Topological Polar Surface Area:
83.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.1
Literature
| Title | Journal |
|---|---|
| Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. | The Lancet. Haematology 20180201 |
| Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. | European journal of pharmacology 20151015 |
| The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms. | Chemico-biological interactions 20140905 |
| Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. | Antimicrobial agents and chemotherapy 20140401 |
| JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. | Journal of immunology research 20140101 |
| Myelofibrosis: an update on current pharmacotherapy and future directions. | Expert opinion on pharmacotherapy 20130501 |
| Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. | Arthritis and rheumatism 20121201 |
| Ruxolitinib: in the treatment of myelofibrosis. | Drugs 20121112 |
| Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. | Expert opinion on pharmacotherapy 20121101 |
| Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. | Blood 20121025 |
| Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. | Journal of the American Academy of Dermatology 20121001 |
| Role of additional novel therapies in myeloproliferative neoplasms. | Hematology/oncology clinics of North America 20121001 |
| Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. | Molecular diagnosis & therapy 20121001 |
| Advances in the management of myelofibrosis. | Cancer control : journal of the Moffitt Cancer Center 20121001 |
| [Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]. | Deutsche medizinische Wochenschrift (1946) 20121001 |
| Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. | Blood 20120927 |
| Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. | Journal of immunology (Baltimore, Md. : 1950) 20120915 |
| Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. | Blood 20120816 |
| Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. | Blood 20120809 |
| How I treat polycythemia vera. | Blood 20120712 |
| Ruxolitinib for myelofibrosis therapy: current context, pros and cons. | Leukemia 20120701 |
| U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120615 |
| The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. | Journal of clinical pharmacology 20120601 |
| Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120601 |
| Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. | Blood 20120517 |
| Ruxolitinib (Jakafi) for myelofibrosis. | The Medical letter on drugs and therapeutics 20120402 |
| Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. | Leukemia 20120401 |
| Breakthroughs in myeloproliferative neoplasms. | Hematology (Amsterdam, Netherlands) 20120401 |
| JAK2 inhibitors and their impact in myeloproliferative neoplasms. | Hematology (Amsterdam, Netherlands) 20120401 |
| JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. | Blood 20120322 |
| New generation small-molecule inhibitors in myeloproliferative neoplasms. | Current opinion in hematology 20120301 |
| Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. | Current hematologic malignancy reports 20120301 |
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. | The New England journal of medicine 20120301 |
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. | The New England journal of medicine 20120301 |
| Ruxolitinib. | Nature reviews. Drug discovery 20120201 |
| Ruxolitinib: the first agent approved for myelofibrosis. | Clinical advances in hematology & oncology : H&O 20120201 |
| Incyte comes of age with JAK inhibitor approval. | Nature biotechnology 20120109 |
| STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. | PloS one 20120101 |
| Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. | Mayo Clinic proceedings 20111201 |
| Ruxolitinib for the treatment of myelofibrosis. | Drugs of today (Barcelona, Spain : 1998) 20111101 |
| Long-term outcome of treatment with ruxolitinib in myelofibrosis. | The New England journal of medicine 20111013 |
| Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. | Future oncology (London, England) 20110901 |
| A potential role of ruxolitinib in leukemia. | Expert opinion on investigational drugs 20110801 |
| Targeting myeloproliferative neoplasms with JAK inhibitors. | Current opinion in hematology 20110301 |
| JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. | Leukemia 20110201 |
| JAK inhibition in myelofibrosis. | The New England journal of medicine 20101216 |
| Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. | Drug metabolism and disposition: the biological fate of chemicals 20101101 |
| Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. | IDrugs : the investigational drugs journal 20100601 |
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. | Blood 20100415 |
| Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. | Organic letters 20090507 |
| Novel strategies for patients with chronic myeloproliferative disorders. | Current opinion in hematology 20090301 |
| Therapeutic potential of JAK2 inhibitors. | Hematology. American Society of Hematology. Education Program 20090101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.